pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›orelabrutinib
drug · small molecule
save

orelabrutinib

Phase 3updated 5mo ago
by $ZBIO Zenas BioPharma, Inc.🔗 ChEMBL
Phase 3
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 18 investigational indications.

targets

Tyrosine-protein kinase BTK

all catalysts(0)

nothing on the calendar yet

Trials studying orelabrutinib

  • phase3A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosisrecruitingn=990
  • phase3A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).not yet recruitingn=280
  • phase3A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosisrecruitingn=705
  • phase2Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZLactive not recruitingn=65
  • phase3A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphomacompletedn=3
  • phase3A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphomarecruitingn=394
  • phase2Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapyrecruitingn=79
  • phase3ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)recruitingn=226

News(2)

  • Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
    InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8…
    biospace · 10d ago
  • Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
    Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.
    fiercebiotech · 11d ago
trade names
Innobruka
generic
orelabrutinib
MOA
Tyrosine-protein kinase BTK inhibitor
indication
Primary Progressive Multiple Sclerosis (PPMS)
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 49m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?